Compare JFU & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | LITS |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 25.7M |
| IPO Year | 2018 | 2003 |
| Metric | JFU | LITS |
|---|---|---|
| Price | $2.68 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 318.7K |
| Earning Date | 12-09-2022 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.69 |
| 52 Week High | $9.48 | $2.97 |
| Indicator | JFU | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 51.36 |
| Support Level | $2.06 | $0.97 |
| Resistance Level | $2.94 | $1.11 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 52.17 | 34.01 |
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.